Quadrature Capital Ltd Purchases New Holdings in Charles River Laboratories International, Inc. $CRL

Quadrature Capital Ltd acquired a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 2nd quarter, HoldingsChannel reports. The firm acquired 17,982 shares of the medical research company’s stock, valued at approximately $2,730,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brooklyn Investment Group raised its stake in shares of Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares during the last quarter. Cromwell Holdings LLC grew its position in Charles River Laboratories International by 542.9% in the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after buying an additional 152 shares during the last quarter. Neo Ivy Capital Management acquired a new position in Charles River Laboratories International in the 2nd quarter valued at $29,000. Allworth Financial LP raised its position in Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after buying an additional 190 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Charles River Laboratories International in the 2nd quarter worth $56,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CRL has been the topic of a number of recent analyst reports. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and increased their price target for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. TD Cowen reduced their price target on Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating for the company in a report on Monday, November 10th. Evercore ISI upped their price objective on Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, October 3rd. Finally, Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $190.86.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $178.14 on Friday. The business has a 50 day moving average price of $171.68 and a 200 day moving average price of $160.16. The company has a market capitalization of $8.77 billion, a P/E ratio of -133.94, a PEG ratio of 4.83 and a beta of 1.53. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $203.01. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. During the same period in the previous year, the business earned $2.59 earnings per share. Charles River Laboratories International’s quarterly revenue was down .5% compared to the same quarter last year. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).